AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2020
Jun 10, 2020
32312_dirs_2020-06-10_677696a5-a2a5-4b49-a5ad-8bba1dae9cd6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-06-08
Reporting Person: Tomasello Shawn (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-06-08 | Stock Option (right to buy) | $28.24 | A | 10000 | Acquired | 2030-06-07 | Ordinary Shares (10000) | Direct |
Footnotes
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year.
More from UroGen Pharma Ltd.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 4